|
|
Volumn 12, Issue 5, 2013, Pages 335-
|
|
Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE;
ADALIMUMAB;
APREMILAST;
CYCLIC AMP;
CYCLOSPORIN;
ETANERCEPT;
INTERLEUKIN 10;
INTERLEUKIN 23;
METHOTREXATE;
PLACEBO;
TOFACITINIB;
TUMOR NECROSIS FACTOR;
DISEASE SEVERITY;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG SAFETY;
ENZYME INHIBITION;
HUMAN;
NOTE;
PRIORITY JOURNAL;
PROTEIN EXPRESSION;
PSORIASIS;
CLINICAL TRIALS, PHASE III AS TOPIC;
CYCLIC AMP;
CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4;
CYTOKINES;
DRUG APPROVAL;
PHOSPHODIESTERASE 4 INHIBITORS;
PSORIASIS;
THALIDOMIDE;
|
|
EID: 84877262247
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd4017 Document Type: Note |
|
Times cited : (6)
|
|
References (0)
|
